Studies reported that overexpression of Oct4 and Sox2 were associated with drug-resistance, including chemotherapy, radiation therapy and target therapy in lung cancer and bladder cancer, malignant mesothelioma cells and osteosarcoma [39–42]. This evidence concerns the gene POU5F1 and urinary bladder cancer.